Tag: KDC-MN-327

  • HU-308

    Synthetic CB2-selective cannabinoid

    A synthetic CB2-selective cannabinoid agonist; a research tool for CB2 pharmacology without psychoactive CB1 activity.

    Abstract

    HU-308 ([4-[4-(1,1-dimethylheptyl)-2,6-dimethoxyphenyl]-6,6-dimethyl-bicyclo[3.1.1]hept-2-en-2-yl]methanol; CAS 256934-39-1; molecular formula C27H42O4; molecular weight 430.62) is a synthetic CB2-selective cannabinoid agonist developed by Mechoulam and colleagues at Hebrew University. The compound is a pinene-scaffold cannabinoid with high CB2 affinity (Ki approximately 23 nM) and minimal CB1 binding (greater than 440-fold selectivity), eliminating the psychoactivity associated with CB1-mediated cannabinoid effects. CB2 is expressed predominantly in peripheral immune cells (macrophages, B cells, T cells, microglia in CNS); selective activation produces anti-inflammatory and analgesic effects without psychotropic side effects. Preclinical studies demonstrate efficacy in inflammatory bowel disease, neuropathic pain, hepatic ischemia, and atherosclerosis models. Plasma half-life is approximately 2 to 3 hours. Used as the canonical CB2-selective research probe in academic immunology and pain research.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.